Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$105.55 USD
-0.84 (-0.79%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $105.45 -0.10 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 141 - 160 ( 512 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Treatment Paradigm Pulse-A Prospective Look at EGFR Inhibitors in NSCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Biotechnology - Relevant Abstracts at EORTC-NCI-AACR 2022
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
ESMO 2022 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended August 19.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
PIONEER Paves the Way for iSM Approval in ''23
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
PIONEER Hits in Non-Advanced SM, Though Questions Arise on Patient Impact; Reit Buy and Lowering Our PT to $80 from $100
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Positive Ahead of Topline PIONEER Data in August ''22 - Our Data Preview
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
KOL Highlights: Discussing Mastocytosis with Dr. Daniel DeAngelo.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department